The cellular fate of glucose and its relevance in type 2 diabetes

Endocrine Reviews

Volumn 25, Issue 5, 2004, Pages 807-830

  Bouché, Clara ^a,b   Serdy, Shanti ^a,b,c   Kahn, C Ronald ^a,b,c   Goldfine, Allison B ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOSLIN DIABETES CENTER   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER; HEXOKINASE; HEXOSAMINE; HEXOSE PHOSPHATE; INSULIN;

ANAEROBIC METABOLISM; BIOSYNTHESIS; CARBOHYDRATE METABOLISM; CITRIC ACID CYCLE; ENZYME PHOSPHORYLATION; GLUCONEOGENESIS; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCOGEN METABOLISM; GLYCOGEN SYNTHESIS; GLYCOLYSIS; HUMAN; HYPERGLYCEMIA; INSULIN DEFICIENCY; INSULIN METABOLISM; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SYNTHESIS; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

BIOLOGICAL TRANSPORT; CELLS; DIABETES MELLITUS, TYPE 2; GLUCONEOGENESIS; GLUCOSE; GLYCOGEN; GLYCOLYSIS; HEXOSAMINES; HEXOSEPHOSPHATES; HUMANS; MONOSACCHARIDE TRANSPORT PROTEINS; PENTOSE PHOSPHATE PATHWAY; PENTOSES; PHOSPHORYLATION;

EID: 5444269110     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2003-0026     Document Type: Review

References (312)

1. DeFronzo RA 1988 Lilly lecture 1987. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667-687
2. Kahn CR 1994 Banting lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43:1066-1084
3. Porte Jr D 1991 Banting lecture 1990. β-cells in type II diabetes mellitus. Diabetes 40:166-180
4. Weyer C, Bogardus C, Mott DM, Pratley RE 1999 The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794
5. Ludvik B, Nolan JJ, Roberts A, Baloga J, Joyce M, Bell JM, Olefsky JM 1997 Evidence for decreased splanchnic glucose uptake after oral glucose administration in non-insulin-dependent diabetes mellitus. J Clin Invest 100:2354-2361
6. DeFronzo RA, Gunnarsson R, Bjorkman O, Olsson M, Wahren J 1985 Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J Clin Invest 76:149-155
7. Shulman GI 2000 Cellular mechanisms of insulin resistance. J Clin Invest 106:171-176
8. Baron AD, Laakso M, Brechtel G, Edelman SV 1991 Reduced capacity and affinity of skeletal muscle for insulin-mediated glucose uptake in noninsulin-dependent diabetic subjects. Effects of insulin therapy. J Clin Invest 87:1186-1194
9. Reaven GM 1991 Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension. Parallels between human disease and rodent models. Diabetes Care 14:195-202
10. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR 1992 Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340:925-929
11. Saltiel AR, Kahn CR 2001 Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414:799-806
12. Virkamaki A, Ueki K, Kahn CR 1999 Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 103:931-943
13. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, Porte Jr D 1993 Quantification of the relationship between insulin sensitivity and β-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42:1663-1672
14. Poitout V, Robertson RP 2002 Minireview: secondary β-cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity. Endocrinology 143:339-342
15. Bernard-Kargar C, Ktorza A 2001 Endocrine pancreas plasticity under physiological and pathological conditions. Diabetes 50(Suppl 1): S30-S35
16. Leibiger B, Moede T, Schwarz T, Brown GR, Kohler M, Leibiger IB, Berggren PO 1998 Short-term regulation of insulin gene transcription by glucose. Proc Natl Acad Sci USA 95:9307-9312
17. Matschinsky FM 1996 Banting lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 45:223-241
18. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR 1999 Tissue-specific knockout of the insulin receptor in pancreatic β cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96:329-339
19. Leibiger B, Leibiger IB, Moede T, Kemper S, Kulkarni RN, Kahn CR, de Vargas LM, Berggren PO 2001 Selective insulin signaling through A and B insulin receptors regulates transcription of insulin and glucokinase genes in pancreatic β cells. Mol Cell 7:559-570
20. Cherrington AD, Williams PE, Harris MS 1978 Relationship between the plasma glucose level and glucose uptake in the conscious dog. Metabolism 27:787-791
21. Bergman RN 1989 Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes 38:1512-1527
22. Ader M, Ni TC, Bergman RN 1997 Glucose effectiveness assessed under dynamic and steady state conditions. Comparability of uptake versus production components. J Clin Invest 99:1187-1199
23. Del Prato S, Riccio A, Vigili de Kreutzenberg S, Dorella M, Tiengo A, DeFronzo RA 1995 Basal plasma insulin levels exert a qualitative but not quantitative effect on glucose-mediated glucose uptake. Am J Physiol 268:E1089-E1095
24. Itani SI, Saha AK, Kurowski TG, Coffin HR, Tornheim K, Ruderman NB 2003 Glucose autoregulates its uptake in skeletal muscle: involvement of AMP-activated protein kinase. Diabetes 52:1635-1640
25. Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, Porte Jr D 1994 The contribution of insulin-dependent and insulin-independent glucose uptake to intravenous glucose tolerance in healthy human subjects. Diabetes 43:587-592
26. Ader M, Pacini G, Yang YJ, Bergman RN 1985 Importance of glucose per se to intravenous glucose tolerance. Comparison of the minimal-model prediction with direct measurements. Diabetes 34:1092-1103
27. Del Prato S, Matsuda M, Simonson DC, Groop LC, Sheehan P, Leonetti F, Bonadonna RC, DeFronzo RA 1997 Studies on the mass action effect of glucose in NIDDM and IDDM: evidence for glucose resistance. Diabetologia 40:687-697
28. Quon MJ, Cochran C, Taylor SI, Eastman RC 1994 Non-insulin-mediated glucose disappearance in subjects with IDDM. Discordance between experimental results and minimal model analysis. Diabetes 43:890-896
29. Finegood DT, Tzur D 1996 Reduced glucose effectiveness associated with reduced insulin release: an artifact of the minimal-model method. Am J Physiol 271:E485-E495
30. Basu A, Caumo A, Bettini F, Gelisio A, Alzaid A, Cobelli C, Rizza RA 1997 Impaired basal glucose effectiveness in NIDDM: contribution of defects in glucose disappearance and production, measured using an optimized minimal model independent protocol. Diabetes 46:421-432
31. Reaven GM 1995 Pathophysiology of insulin resistance in human disease. Physiol Rev 75:473-486
32. Unger RH 2003 Lipid overload and overflow: metabolic trauma and the metabolic syndrome. Trends Endocrinol Metab 14:398-403
33. Unger RH 2003 Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 144:5159-5165
34. Bell GI, Burant CF, Takeda J, Gould GW 1993 Structure and function of mammalian facilitative sugar transporters. J Biol Chem 268:19161-19164
35. Joost HG, Bell GI, Best JD, Birnbaum MJ, Charron MJ, Chen YT, Doege H, James DE, Lodish HF, Moley KH, Moley JF, Mueckler M, Rogers S, Schurmann A, Seino S, Thorens B 2002 Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab 282:E974-E976
36. Barnes K, Ingram JC, Porras OH, Barros LF, Hudson ER, Fryer LG, Foufelle F, Carling D, Hardie DG, Baldwin SA 2002 Activation of GLUT1 by metabolic and osmotic stress: potential involvement of AMP-activated protein kinase (AMPK). J Cell Sci 115:2433-2442
37. Hwang DY, Ismail-Beigi F 2001 Stimulation of GLUT-1 glucose transporter expression in response to hyperosmolarity. Am J Physiol Cell Physiol 281:C1365-C1372
38. Clarke JF, Young PW, Yonezawa K, Kasuga M, Holman GD 1994 Inhibition of the translocation of GLUT1 and GLUT4 in 3T3-L1 cells by the phosphatidylinositol 3-kinase inhibitor, wortmannin. Biochem J 300(Pt 3):631-635
39. Shi Y, Liu H, Vanderburg G, Samuel SJ, Ismail-Beigi F, Jung CY 1995 Modulation of GLUT1 intrinsic activity in clone 9 cells by inhibition of oxidative phosphorylation. J Biol Chem 270:21772-21778
40. Seidner G, Alvarez MG, Yeh JI, O'Driscoll KR, Klepper J, Stump TS, Wang D, Spinner NB, Birnbaum MJ, De Vivo DC 1998 GLUT-1 deficiency syndrome caused by haploinsufficiency of the blood-brain barrier hexose carrier. Nat Genet 18:188-191
41. Heijnen HF, Oorschot V, Sixma JJ, Slot JW, James DE 1997 Thrombin stimulates glucose transport in human platelets via the translocation of the glucose transporter GLUT-3 from α-granules to the cell surface. J Cell Biol 138:323-330
42. Reagan LP, Magarinos AM, Lucas LR, van Bueren A, McCall AL, McEwen BS 1999 Regulation of GLUT-3 glucose transporter in the hippocampus of diabetic rats subjected to stress. Am J Physiol 276:E879-E886
43. Jhun BH, Rampal AL, Liu H, Lachaal M, Jung CY 1992 Effects of insulin on steady state kinetics of GLUT4 subcellular distribution in rat adipocytes. Evidence of constitutive GLUT4 recycling. J Biol Chem 267:17710-17715
44. Rodnick KJ, Piper RC, Slot JW, James DE 1992 Interaction of insulin and exercise on glucose transport in muscle. Diabetes Care 15:1679-1689
45. Leturque A, Loizeau M, Vaulont S, Salminen M, Girard J 1996 Improvement of insulin action in diabetic transgenic mice selectively overexpressing GLUT4 in skeletal muscle. Diabetes 45:23-27
46. Tsao TS, Burcelin R, Katz EB, Huang L, Charron MJ 1996 Enhanced insulin action due to targeted GLUT4 overexpression exclusively in muscle. Diabetes 45:28-36
47. Shepherd PR, Gnudi L, Tozzo E, Yang H, Leach F, Kahn BB 1993 Adipose cell hyperplasia and enhanced glucose disposal in transgenic mice overexpressing GLUT4 selectively in adipose tissue. J Biol Chem 268:22243-22246
48. Zisman A, Peroni OD, Abel ED, Michael MD, Mauvais-Jarvis F, Lowell BB, Wojtaszewski JF, Hirshman MF, Virkamaki A, Goodyear LJ, Kahn CR, Kahn BB 2000 Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med 6:924-928
49. Katz EB, Stenbit AE, Hatton K, DePinho R, Charron MJ 1995 Cardiac and adipose tissue abnormalities but not diabetes in mice deficient in GLUT4. Nature 377:151-155
50. Stenbit AE, Burcelin R, Katz EB, Tsao TS, Gautier N, Charron MJ, Le Marchand-Brustel Y 1996 Diverse effects of Glut 4 ablation on glucose uptake and glycogen synthesis in red and white skeletal muscle. J Clin Invest 98:629-634
51. Hogan A, Heyner S, Charron MJ, Copeland NG, Gilbert DJ, Jenkins NA, Thorens B, Schultz GA 1991 Glucose transporter gene expression in early mouse embryos. Development 113:363-372
52. Levitsky LL, Zheng Q, Mink K, Rhoads DB 1994 GLUT-1 and GLUT-2 mRNA, protein, and glucose transporter activity in cultured fetal and adult hepatocytes. Am J Physiol 267:E88-E94
53. Noel LE, Newgard CB 1997 Structural domains that contribute to substrate specificity in facilitated glucose transporters are distinct from those involved in kinetic function: studies with GLUT-1/GLUT-2 chimeras. Biochemistry 36:5465-5475
54. Tiedge M, Lenzen S 1991 Regulation of glucokinase and GLUT-2 glucose-transporter gene expression in pancreatic β-cells. Biochem J 279(Pt 3):899-901
55. Tal M, Liang Y, Najafi H, Lodish HF, Matschinsky FM 1992 Expression and function of GLUT-1 and GLUT-2 glucose transporter isoforms in cells of cultured rat pancreatic islets. J Biol Chem 267:17241-17247
56. Burcelin R, Eddouks M, Kande J, Assan R, Girard J 1992 Evidence that GLUT-2 mRNA and protein concentrations are decreased by hyperinsulinaemia and increased by hyperglycaemia in liver of diabetic rats. Biochem J 288(Pt 2):675-679
57. Guillam MT, Hummler E, Schaerer E, Yeh JI, Birnbaum MJ, Beermann F, Schmidt A, Deriaz N, Thorens B, Wu JY 1997 Early diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2. Nat Genet 17:327-330
58. Santer R, Schneppenheim R, Dombrowski A, Gotze H, Steinmann B, Schaub J 1997 Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome. Nat Genet 17:324-326
59. Santer R, Groth S, Kinner M, Dombrowski A, Berry GT, Brodehl J, Leonard JV, Moses S, Norgren S, Skovby F, Schneppenheim R, Steinmann B, Schaub J 2002 The mutation spectrum of the facuitative glucose transporter gene SLC2A2 (GLUT2) in patients with Fanconi-Bickel syndrome. Hum Genet 110:21-29
60. Efrat S, Tal M, Lodish HF 1994 The pancreatic β-cell glucose sensor. Trends Biochem Sci 19:535-538
61. Porzio O, Marlier LN, Federici M, Hribal ML, Magnaterra R, Lauro D, Fusco A, Sesti G, Borboni P 1999 GLUT2 and glucokinase expression is coordinately regulated by sulfonylurea. Mol Cell Endocrinol 153:155-161
62. Orci L, Ravazzola M, Baetens D, Inman L, Amherdt M, Peterson RG, Newgard CB, Johnson JH, Unger RH 1990 Evidence that down-regulation of β-cell glucose transporters in non-insulin-dependent diabetes may be the cause of diabetic hyperglycemia. Proc Natl Acad Sci USA 87:9953-9957
63. Doege H, Bocianski A, Scheepers A, Axer H, Eckel J, Joost HG, Schurmann A 2001 Characterization of human glucose transporter (GLUT) 11 (encoded by SLC2A11), a novel sugar-transport facilitator specifically expressed in heart and skeletal muscle. Biochem J 359:443-449
64. Lisinski I, Schurmann A, Joost HG, Cushman SW, Al-Hasani H 2001 Targeting of GLUT6 (formerly GLUT9) and GLUT8 in rat adipose cells. Biochem J 358:517-522
65. Ibberson M, Uldry M, Thorens B 2000 GLUTX1, a novel mammalian glucose transporter expressed in the central nervous system and insulin-sensitive tissues. J Biol Chem 275:4607-4612
66. Dawson PA, Mychaleckyj JC, Fossey SC, Mihic SJ, Craddock AL, Bowden DW 2001 Sequence and functional analysis of GLUT10: a glucose transporter in the type 2 diabetes-linked region of chromosome 20q12-13.1. Mol Genet Metab 74:186-199
67. Rogers S, Macheda ML, Docherty SE, Carty MD, Henderson MA, Soeller WC, Gibbs EM, James DE, Best JD 2002 Identification of a novel glucose transporter-like protein-GLUT-12. Am J Physiol Endocrinol Metab 282:E733-E738
68. Wright EM 2001 Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 280:F10-F18
69. Martin MG, Turk E, Lostao MP, Kerner C, Wright EM 1996 Defects in Na+/glucose cotransporter (SGLT1) trafficking and function cause glucose-galactose malabsorption. Nat Genet 12:216-220
70. Vestri S, Okamoto MM, de Freitas HS, Aparecida Dos Santos R, Nunes MT, Morimatsu M, Heimann JC, Machado UF 2001 Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol 182:105-112
71. van den Heuvel LP, Assink K, Willemsen M, Monnens L 2002 Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 111:544-547
72. Fink RI, Wallace P, Brechtel G, Olefsky JM 1992 Evidence that glucose transport is rate-limiting for in vivo glucose uptake. Metabolism 41:897-902
73. Yki-Jarvinen H, Young AA, Lamkin C, Foley JE 1987 Kinetics of glucose disposal in whole body and across the forearm in man. J Clin Invest 79:1713-1719
74. Yki-Jarvinen H, Vuorinen-Markkola H, Koranyi L, Bourey R, Tordjman K, Mueckler M, Permutt AM, Koivisto VA 1992 Defect in insulin action on expression of the muscle/adipose tissue glucose transporter gene in skeletal muscle of type 1 diabetic patients. J Clin Endocrinol Metab 75:795-799
75. Butler PC, Kryshak EJ, Marsh M, Rizza RA 1990 Effect of insulin on oxidation of intracellularly and extracellularly derived glucose in patients with NIDDM. Evidence for primary defect in glucose transport and/or phosphorylation but not oxidation. Diabetes 39:1373-1380
76. Cline GW, Petersen KF, Krssak M, Shen J, Hundal RS, Trajanoski Z, Inzucchi S, Dresner A, Rothman DL, Shulman GI 1999 Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med 341:240-246
77. Rothman DL, Magnusson I, Cline G, Gerard D, Kahn CR, Shulman RG, Shulman GI 1995 Decreased muscle glucose transport/ phosphorylation is an early defect in the pathogenesis of non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 92:983-987
78. Zierath JR, He L, Guma A, Odegoard Wahlstrom E, Klip A, Wallberg-Henriksson H 1996 Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia 39:1180-1189
79. Garvey WT, Maianu L, Zhu JH, Brechtel-Hook G, Wallace P, Baron AD 1998 Evidence for defects in the trafficking and translocation of GLUT4 glucose transporters in skeletal muscle as a cause of human insulin resistance. J Clin Invest 101:2377-2386
80. Pedersen O, Bak JF, Andersen PH, Lund S, Moller DE, Flier JS, Kahn BB 1990 Evidence against altered expression of GLUT1 or GLUT4 in skeletal muscle of patients with obesity or NIDDM. Diabetes 39:865-870
81. Maianu L, Keller SR, Garvey WT 2001 Adipocytes exhibit abnormal subcellular distribution and translocation of vesicles containing glucose transporter 4 and insulin-regulated aminopeptidase in type 2 diabetes mellitus: implications regarding defects in vesicle trafficking. J Clin Endocrinol Metab 86:5450-5456
82. Garvey WT, Maianu L, Huecksteadt TP, Birnbaum MJ, Molina JM, Ciaraldi TP 1991 Pretranslational suppression of a glucose transporter protein causes insulin resistance in adipocytes from patients with non-insulin-dependent diabetes mellitus and obesity. J Clin Invest 87:1072-1081
83. Buse JB, Yasuda K, Lay TP, Seo TS, Olson AL, Pessin JE, Karam JH, Seino S, Bell GI 1992 Human GLUT4/muscle-fat glucose-transporter gene. Characterization and genetic variation. Diabetes 41:1436-1445
84. Goodyear LJ, Kahn BB 1998 Exercise, glucose transport, and insulin sensitivity. Annu Rev Med 49:235-261
85. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403
86. Vranic M, Berger M 1979 Exercise and diabetes mellitus. Diabetes 28:147-163
87. McVie-Wylie AJ, Lamson DR, Chen YT 2001 Molecular cloning of a novel member of the GLUT family of transporters, SLC2a10 (GLUT10), localized on chromosome 20q13.1: a candidate gene for NIDDM susceptibility. Genomics 72:113-117
88. Cha JY, Kim HS, Kim HI, Im SS, Kim SY, Kim JW, Yeh BI, Ahn YH 2002 Analysis of polymorphism of the GLUT2 promoter in NIDDM patients and its functional consequence to the promoter activity. Ann Clin Lab Sci 32:114-122
89. Muller G, Wied S 1993 The sulfonylurea drug, glimepiride, stimulates glucose transport, glucose transporter translocation, and dephosphorylation in insulin-resistant rat adipocytes in vitro. Diabetes 42:1852-1867
90. Tsiani E, Ramlal T, Leiter LA, Klip A, Fantus IG 1995 Stimulation of glucose uptake and increased plasma membrane content of glucose transporters in L6 skeletal muscle cells by the sulfonylureas gliclazide and glyburide. Endocrinology 136:2505-2512
91. Matthaei S, Hamann A, Klein HH, Benecke H, Kreymann G, Flier JS, Greten H 1991 Association of metformin's effect to increase insulin-stimulated glucose transport with potentiation of insulin-induced translocation of glucose transporters from intracellular pool to plasma membrane in rat adipocytes. Diabetes 40:850-857
92. Galuska D, Nolte LA, Zierath JR, Wallberg-Henriksson H 1994 Effect of metformin on insulin-stimulated glucose transport in isolated skeletal muscle obtained from patients with NIDDM. Diabetologia 37:826-832
93. Hallsten K, Virtanen KA, Lonnqvist F, Sipila H, Oksanen A, Viljanen T, Ronnemaa T, Viikari J, Knuuti J, Nuutila P 2002 Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Diabetes 51:3479-3485
94. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE 2001 Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174
95. Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF 2002 The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802
96. Park KS, Ciaraldi TP, Lindgren K, Abrams-Carter L, Mudaliar S, Nikoulina SE, Tufari SR, Veerkamp JH, Vidal-Puig A, Henry RR 1998 Troglitazone effects on gene expression in human skeletal muscle of type II diabetes involve up-regulation of peroxisome proliferator-activated receptor-γ. J Clin Endocrinol Metab 83:2830-2835
97. Asano T, Wakisaka M, Yoshinari M, Nakamura S, Doi Y, Fujishima M 2000 Troglitazone enhances glycolysis and improves intracellular glucose metabolism in rat mesangial cells. Metabolism 49:308-313
98. Yonemitsu S, Nishimura H, Shintani M, Inoue R, Yamamoto Y, Masuzaki H, Ogawa Y, Hosoda K, Inoue G, Hayashi T, Nakao K 2001 Troglitazone induces GLUT4 translocation in L6 myorubes. Diabetes 50:1093-1101
99. Fryer LG, Parbu-Patel A, Carling D 2002 The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277:25226-25232
100. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI 1998 Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867-872
101. Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI 2000 Mechanism of troglitazone action in type 2 diabetes. Diabetes 49:827-831
102. Cardenas ML, Cornish-Bowden A, Ureta T 1998 Evolution and regulatory role of the hexokinases. Biochim Biophys Acta 1401:242-264
103. Coerver KA, Gray SM, Barnes JE, Armstrong DL, McCabe ER 1998 Developmental expression of hexokinase 1 and 3 in rats. Histochem Cell Biol 109:75-86
104. Ehsani-Zonouz A, Golestani A, Nemat-Gorgani M 2001 Interaction of hexokinase with the outer mitochondrial membrane and a hydrophobic matrix. Mol Cell Biochem 223:81-87
105. Liu X, Kim CS, Kurbanov FT, Honzatko RB, Fromm HJ 1999 Dual mechanisms for glucose 6-phosphate inhibition of human brain hexokinase. J Biol Chem 274:31155-31159
106. Arora KK, Filburn CR, Pedersen PL 1993 Structure/function relationships in hexokinase. Site-directed mutational analyses and characterization of overexpressed fragments implicate different functiong for the N- and C-terminal halves of the enzyme. J Biol Chem 268:18259-18266
107. Printz RL, Koch S, Potter LR, O'Doherty RM, Tiesinga JJ, Moritz S, Granner DK 1993 Hexokinase II mRNA and gene structure, regulation by insulin, and evolution. J Biol Chem 268:5209-5219
108. Chang PY, Jensen J, Printz RL, Granner DK, Ivy JL, Moller DE 1996 Overexpression of hexokinase II in transgenic mice. Evidence that increased phosphorylation augments muscle glucose uptake. J Biol Chem 271:14834-14839
109. Ritov VB, Kelley DE 2001 Hexokinase isozyme distribution in human skeletal muscle. Diabetes 50:1253-1262
110. Koval JA, DeFronzo RA, O'Doherty RM, Printz R, Ardehali H, Granner DK, Mandarino LJ 1998 Regulation of hexokinase II activity and expression in human muscle by moderate exercise. Am J Physiol 274:E304-E308
111. Jones JP, Dohm GL 1997 Regulation of glucose transporter GLUT-4 and hexokinase II gene transcription by insulin and epinephrine. Am J Physiol 273:E682-E687
112. Vogt C, Ardehali H, Iozzo P, Yki-Jarvinen H, Koval J, Maezono K, Pendergrass M, Printz R, Granner D, DeFronzo R, Mandarino L 2000 Regulation of hexokinase II expression in human skeletal muscle in vivo. Metabolism 49:814-818
113. Osawa H, Sutherland C, Robey RB, Printz RL, Granner DK 1996 Analysis of the signaling pathway involved in the regulation of hexokinase II gene transcription by insulin. J Biol Chem 271:16690-16694
114. Robey RB, Ma J, Santos AV, Noboa OA, Coy PE, Bryson JM 2002 Regulation of mesangial cell hexokinase activity and expression by heparin-binding epidermal growth factor-like growth factor: epidermal growth factors and phorbol esters increase glucose metabolism via a common mechanism involving classic mitogen-activated protein kinase pathway activation and induction of hexokinase II expression. J Biol Chem 277:14370-14378
115. Heikkinen S, Pietila M, Halmekyto M, Suppola S, Pirinen E, Deeb SS, Janne J, Laakso M 1999 Hexokinase II-deficient mice. Prenatal death of homozygotes without disturbances in glucose tolerance in heterozygotes. J Biol Chem 274:22517-22523
116. Halseth AE, Bracy DP, Wasserman DH 1999 Overexpression of hexokinase II increases insulin and exercise-stimulated muscle glucose uptake in vivo. Am J Physiol 276:E70-E77
117. Preller A, Wilson JE 1992 Localization of the type III isozyme of hexokinase at the nuclear periphery. Arch Biochem Biophys 294:482-492
118. Matschinsky FM, Glaser B, Magnuson MA 1998 Pancreatic β-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes 47:307-315
119. Bedoya FJ, Matschinsky FM, Shimizu T, O'Neil JJ, Appel MC 1986 Differential regulation of glucokinase activity in pancreatic islets and liver of the rat. J Biol Chem 261:10760-10764
120. Magnuson MA 1990 Glucokinase gene structure. Functional implications of molecular genetic studies. Diabetes 39:523-527
121. Brown KS, Kalinowski SS, Megill JR, Durham SK, Mookhtiar KA 1997 Glucokinase regulatory protein may interact with glucokinase in the hepatocyte nucleus. Diabetes 46:179-186
122. Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, Shelton KD, Lindner J, Cherrington AD, Magnuson MA 1999 Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic β cell-specific gene knock-outs using Cre recombinase. J Biol Chem 274:305-315
123. Christ B, Probst I, Jungermann K 1986 Antagonistic regulation of the glucose/glucose 6-phosphate cycle by insulin and glucagon in cultured hepatocytes. Biochem J 238:185-191
124. Lange AJ, Argaud D, el-Maghrabi MR, Pan W, Maitra SR, Pilkis SJ 1994 Isolation of a cDNA for the catalytic subunit of rat liver glucose-6- phosphatase: regulation of gene expression in FAO hepatoma cells by insulin, dexamethasone and cAMP. Biochem Biophys Res Commun 201:302-309
125. Chou JY 2001 The molecular basis of type 1 glycogen storage diseases. Curr Mol Med 1:25-44
126. Trinh KY, O'Doherty RM, Anderson P, Lange AJ, Newgard CB 1998 Perturbation of fuel homeostasis caused by overexpression of the glucose-6-phosphatase catalytic subunit in liver of normal rats. J Biol Chem 273:31615-31620
127. Iizuka K, Nakajima H, Ono A, Okita K, Miyazaki J, Miyagawa J, Namba M, Hanafusa T, Matsuzawa Y 2000 Stable overexpression of the glucose-6-phosphatase catalytic subunit attenuates glucose sensitivity of insulin secretion from a mouse pancreatic β-cell line. J Endocrinol 164:307-314
128. Vestergaard H, Bjorbaek C, Hansen T, Larsen FS, Granner DK, Pedersen O 1995 Impaired activity and gene expression of hexokinase II in muscle from non-insulin-dependent diabetes mellitus patients. J Clin Invest 96:2639-2645
129. Ducluzeau PH, Perretti N, Laville M, Andreelli F, Vega N, Riou JP, Vidal H 2001 Regulation by insulin of gene expression in human skeletal muscle and adipose tissue. Evidence for specific defects in type 2 diabetes. Diabetes 50:1134-1142
130. Pendergrass M, Koval J, Vogt C, Yki-Jarvinen H, Iozzo P, Pipek R, Ardehali H, Printz R, Granner D, DeFronzo RA, Mandarino LJ 1998 Insulin-induced hexokinase II expression is reduced in obesity and NIDDM. Diabetes 47:387-394
131. Laakso M, Malkki M, Kekalainen P, Kuusisto J, Deeb SS 1995 Polymorphisms of the human hexokinase II gene: lack of association with NIDDM and insulin resistance. Diabetologia 38:617-622
132. Ardehali H, Tiller GE, Printz RL, Mochizuki H, Prochazka M, Granner DK 1996 A novel (TA)n polymorphism in the hexokinase II gene: application to noninsulin-dependent diabetes mellitus in the Pima Indians. Hum Genet 97:482-485
133. Froguel P, Zouali H, Vionnet N, Velho G, Vaxillaire M, Sun F, Lesage S, Stoffel M, Takeda J, Passa P, Permutt MA, Beckmann JS, Bell GI, Cohen D 1993 Familial hyperglycemia due to mutations in glucokinase. Definition of a subtype of diabetes mellitus. N Engl J Med 328:697-702
134. Froguel P, Vaxillaire M, Sun F, Velho G, Zouali H, Butel MO, Lesage S, Vionnet N, Clement K, Fougerousse F, Tanizawa Y, Weissenbach J, Beckmann JS, Lathrop GM, Passa P, Permutt A, Cohen D 1992 Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus. Nature 356:162-164
135. Hattersley AT, Turner RC, Permutt MA, Patel P, Tanizawa Y, Chiu KC, O'Rahilly S, Watkins PJ, Wainscoat JS 1992 Linkage of type 2 diabetes to the glucokinase gene. Lancet 339:1307-1310
136. Caro JF, Triester S, Patel VK, Tapscott EB, Frazier NL, Dohm GL 1995 Liver glucokinase: decreased activity in patients with type II diabetes. Horm Metab Res 27:19-22
137. Basu A, Basu R, Shah P, Vella A, Johnson CM, Nair KS, Jensen MD, Schwenk WF, Rizza RA 2000 Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity. Diabetes 49:272-283
138. Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, Stanley CA, Thornton PS, Permutt MA, Matschinsky FM, Herold KC 1998 Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med 338:226-230
139. Christesen HB, Jacobsen BB, Odili S, Buettger C, Cuesta-Munoz A, Hansen T, Brusgaard K, Massa O, Magnuson MA, Shiota C, Matschinsky FM, Barbetti F 2002 The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. Diabetes 51:1240-1246
140. Vionnet N, Hani EH, Lesage S, Philippi A, Hager J, Varret M, Stoffel M, Tanizawa Y, Chiu KC, Glaser B, Permutt MA, Passa P, Demenais F, Froguel P 1997 Genetics of NIDDM in France: studies with 19 candidate genes in affected sib pairs. Diabetes 46:1062-1068
141. Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, Guertin KR, Hilliard DW, Kester RF, Mahaney PE, Marcus L, Qi L, Spence CL, Tengi J, Magnuson MA, Chu CA, Dvorozniak MT, Matschinsky FM, Grippo JF 2003 Allosteric activators of glucokinase: potential role in diabetes therapy. Science 301:370-373
142. Mevorach M, Giacca A, Aharon Y, Hawkins M, Shamoon H, Rossetti L 1998 Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus. J Clin Invest 102:744-753
143. Clore JN, Stillman J, Sugerman H 2000 Glucose-6-phosphatase flux in vitro is increased in type 2 diabetes. Diabetes 49:969-974
144. Mithieux G, Guignot L, Bordet JC, Wiernsperger N 2002 Intrahepatic mechanisms underlying the effect of metformin in decreasing basal glucose production in rats fed a high-fat diet. Diabetes 51:139-143
145. Chakrabarti R, Vikramadithyan RK, Kumar MP, Kumar SK, Mamidi NV, Misra P, Suresh J, Hiriyan J, Rao CS, Rajagopalan R 2002 PMT13, a pyrimidone analogue of thiazolidinedione improves insulin resistance-associated disorders in animal models of type 2 diabetes. Diabetes Obes Metab 4:319-328
146. Davies GF, Khandelwal RL, Roesler WJ 1999 Troglitazone inhibits expression of the phosphoenolpyruvate carboxykinase gene by an insulin-independent mechanism. Biochim Biophys Acta 1451:122-131
147. Randle PJ, Priestman DA, Mistry S, Halsall A 1994 Mechanisms modifying glucose oxidation in diabetes mellitus. Diabetologia 37(Suppl 2):S155-S161
148. Sugden MC, Kraus A, Harris RA, Holness MJ 2000 Fibre-type specific modification of the activity and regulation of skeletal muscle pyruvate dehydrogenase kinase (PDK) by prolonged starvation and refeeding is associated with targeted regulation of PDK isoenzyme 4 expression. Biochem J 346(Pt 3):651-657
149. Sugden MC, Bulmer K, Augustine D, Holness MJ 2001 Selective modification of pyruvate dehydrogenase kinase isoform expression in rat pancreatic islets elicited by starvation and activation of peroxisome proliferator-activated receptor-α: implications for glucose-stimulated insulin secretion. Diabetes 50:2729-2736
150. Wu P, Blair PV, Sato J, Jaskiewicz J, Popov KM, Harris RA 2000 Starvation increases the amount of pyruvate dehydrogenase kinase in several mammalian tissues. Arch Biochem Biophys 381:1-7
151. Coleman DL, Kuzava JE 1991 Genetic regulation of malic enzyme activity in the mouse. J Biol Chem 266:21997-22002
152. Nakai N, Miyazaki Y, Sato Y, Oshida Y, Nagasaki M, Tanaka M, Nakashima K, Shimomura Y 2002 Exercise training increases the activity of pyruvate dehydrogenase complex in skeletal muscle of diabetic rats. Endocr J 49:547-554
153. Mostert M, Rabbone I, Piccinini M, Curto M, Vai S, Musso A, Rinaudo MT 1999 Derangements of pyruvate dehydrogenase in circulating lymphocytes of NIDDM
154. Wilson JE 1995 Hexokinases. Rev Physiol Biochem Pharmacol 126:65-198
155. Wilson JE 2003 Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J Exp Biol 206:2049-2057
156. Randle PJ, Garland PB, Hales CN, Newsholme EA 1963 The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785-789
157. Maizels EZ, Ruderman NB, Goodman MN, Lau D 1977 Effect of acetoacetate on glucose metabolism in the soleus and extensor digitorum longus muscles of the rat. Biochem J 162:557-568
158. Randle PJ, Priestman DA, Mistry SC, Halsall A 1994 Glucose fatty acid interactions and the regulation of glucose disposal. J Cell Biochem 55 Suppl:1-11
159. Ruderman NB, Saha AK, Vavvas D, Witters LA 1999 Malonyl-CoA, fuel sensing, and insulin resistance. Am J Physiol 276:E1-E18
160. Ruderman NB, Saha AK, Kraegen EW 2003 Minireview: malonyl CoA, AMP-activated protein kinase, and adiposity. Endocrinology 144:5166-5171
161. Silva JP, Kohler M, Graff C, Oldfors A, Magnuson MA, Berggren PO, Larsson NG 2000 Impaired insulin secretion and β-cell loss in tissue-specific knockout mice with mitochondrial diabetes. Nat Genet 26:336-340
162. Williamson JR, Cooper RH 1980 Regulation of the citric acid cycle in mammalian systems. FEBS Lett 117 Suppl:K73-K85
163. Rustin P, Bourgeron T, Parfait B, Chretien D, Munnich A, Rotig A 1997 Inborn errors of the Krebs cycle: a group of unusual mitochondrial diseases in human. Biochim Biophys Acta 1361:185-197
164. Sugden MC, Holness MJ 2002 Therapeutic potential of the mammalian pyruvate dehydrogenase kinases in the prevention of hyperglycaemia. Curr Drug Targets Immune Endocr Metabol Disord 2:151-165
165. Huang B, Wu P, Bowker-Kinley MM, Harris RA 2002 Regulation of pyruvate dehydrogenase kinase expression by peroxisome proliferator-activated receptor-α ligands, glucocorticoids, and insulin. Diabetes 51:276-283
166. Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, Skoldberg F, Husebye ES, Eng C, Maher ER 2001 Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69:49-54
167. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance RR, Olpin S, Bevan S, Barker K, Hearle N, Houlston RS, Kiuru M, Lehtonen R, Karhu A, Vilkki S, Laiho P, Eklund C, Vierimaa O, Aittomaki K, Hietala M, Sistonen P, Paetau A, Salovaara R, Herva R, Launonen V, Aaltonen LA 2002 Germline mutations in FH pre-dispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 30:406-410
168. Duke T 1999 Dysoxia and lactate. Arch Dis Child 81:343-350
169. McLane JA, Holloszy JO 1979 Glycogen synthesis from lactate in the three types of skeletal muscle. J Biol Chem 254:6548-6553
170. Barthel A, Schmoll D 2003 Novel concepts in insulin regulation of hepatic gluconeogenesis. Am J Physiol Endocrinol Metab 285:E685-E692
171. Del Prato S, Bonadonna RC, Bonora E, Gulli G, Solini A, Shank M, DeFronzo RA 1993 Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus. J Clin Invest 91:484-494
172. Revers RR, Fink R, Griffin J, Olefsky JM, Kolterman OG 1984 Influence of hyperglycemia on insulin's in vivo effects in type II diabetes. J Clin Invest 73:664-672
173. Kelley DE, Mandarino LJ 1990 Hyperglycemia normalizes insulin-stimulated skeletal muscle glucose oxidation and storage in non-insulin-dependent diabetes mellitus. J Clin Invest 86:1999-2007
174. Henquin JC 2000 Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes 49:1751-1760
175. Ristow M, Vorgerd M, Mohlig M, Schatz H, Pfeiffer A 1997 Deficiency of phosphofructo-1-kinase/muscle subtype in humans impairs insulin secretion and causes insulin resistance. J Clin Invest 100:2833-2841
176. Mandarino LJ, Consoli A, Kelley DE, Reilly JJ, Nurjhan N 1990 Fasting hyperglycemia normalizes oxidative and nonoxidative pathways of insulin-stimulated glucose metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 71:1544-1551
177. Majer M, Popov KM, Harris RA, Bogardus C, Prochazka M 1998 Insulin downregulates pyruvate dehydrogenase kinase (PDK) mRNA: potential mechanism contributing to increased lipid oxidation in insulin-resistant subjects. Mol Genet Metab 65:181-186
178. Gerbitz KD, Gempel K, Brdiczka D 1996 Mitochondria and diabetes. Genetic, biochemical, and clinical implications of the cellular energy circuit. Diabetes 45:113-126
179. Velho G, Byrne MM, Clement K, Sturis J, Pueyo ME, Blanche H, Vionnet N, Fiet J, Passa P, Robert JJ, Polonsky KS, Froguel P 1996 Clinical phenotypes, insulin secretion, and insulin sensitivity in kindreds with maternally inherited diabetes and deafness due to mitochondrial tRNALeu(UUR) gene mutation. Diabetes 45:478-487
180. Kadowaki T, Kadowaki H, Mori Y, Tobe K, Sakuta R, Suzuki Y, Tanabe Y, Sakura H, Awata T, Goto Y, Hayakawa T, Matsuoka K, Kawamori R, Kamada T, Horai S, Nonaka I, Hagura R, Akanuma Y, Yazaki Y 1994 A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. N Engl J Med 330:962-968
181. Lee HK, Song JH, Shin CS, Park DJ, Park KS, Lee KU, Koh CS 1998 Decreased mitochondrial DNA content in peripheral blood precedes the development of non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 42:161-167
182. Kelley DE, He J, Menshikova EV, Ritov VB 2002 Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51:2944-2950
183. Petersen KF, Befroy D, Dufour S, Dziura J, Ariyan C, Rothman DL, DiPietro L, Cline GW, Shulman GI 2003 Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300:1140-1142
184. Yang X, Pratley RE, Tokraks S, Bogardus C, Permana PA 2002 Microarray profiling of skeletal muscle tissues from equally obese, non-diabetic insulin-sensitive and insulin-resistant Pima Indians. Diabetologia 45:1584-1593
185. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, Kashyap S, Miyazaki Y, Kohane I, Costello M, Saccone R, Landaker EJ, Goldfine AB, Mun E, DeFronzo R, Finlayson J, Kahn CR, Mandarino LJ 2003 Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 100:8466-8471
186. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC 2003 PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267-273
187. Puigserver P, Wu Z, Park CW, Graves R, Wright M, Spiegelman BM 1998 A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92:829-839
188. Puigserver P, Spiegelman BM 2003 Peroxisome proliferator-activated receptor-γ coactivator 1 α (PGC-1 α): transcriptional coactivator and metabolic regulator. Endocr Rev 24:78-90
189. Stone S, Abkevich V, Hunt SC, Gutin A, Russell DL, Neff CD, Riley R, Frech GC, Hensel CH, Jammulapati S, Potter J, Sexton D, Tran T, Gibbs D, Iliev D, Gress R, Bloomquist B, Amatruda J, Rae PM, Adams TD, Skolnick MH, Shattuck D 2002 A major predisposition locus for severe obesity, at 4p15-p14. Am J Hum Genet 70:1459-1468
190. Ek J, Andersen G, Urhammer SA, Gaede PH, Drivsholm T, Borch-Johnsen K, Hansen T, Pedersen O 2001 Mutation analysis of peroxisome proliferator-activated receptor-γ coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to type II diabetes mellitus. Diabetologia 44:2220-2226
191. Lacquemant C, Chikri M, Boutin P, Samson C, Froguel P 2002 No association between the G482S polymorphism of the proliferator-activated receptor-γ coactivator-1 (PGC-1) gene and type II diabetes in French Caucasias. Diabetologia 45:602-603; author reply, 604
192. Sirover MA 1997 Role of the glycolytic protein, glyceraldehyde-3- phosphate dehydrogenase, in normal cell function and in cell pathology. J Cell Biochem 66:133-140
193. Du X, Matsumura T, Edelstein D, Rossetti L, Zsengeller Z, Szabo C, Brownlee M 2003 Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112:1049-1057
194. Gastaldelli A, Toschi E, Pettiti M, Frascerra S, Quinones-Galvan A, Sironi AM, Natali A, Ferrannini E 2001 Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients. Diabetes 50:1807-1812
195. Yoshiuchi I, Shingu R, Nakajima H, Hamaguchi T, Horikawa Y, Yamasaki T, Oue T, Ono A, Miyagawa JI, Namba M, Hanafusa T, Matsuzawa Y 1998 Mutation/polymorphism scanning of glucose-6-phosphatase gene promoter in noninsulin-dependent diabetes mellitus patients. J Clin Endocrinol Metab 83:1016-1019
196. Bergman RN, Ader M 2000 Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 11:351-356
197. Shah P, Vella A, Basu A, Basu R, Adkins A, Schwenk WF, Johnson CM, Nair KS, Jensen MD, Rizza RA 2002 Effects of free fatty acids and glycerol on splanchnic glucose metabolism and insulin extraction in nondiabetic humans. Diabetes 51:301-310
198. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI 2000 Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49:2063-2069
199. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE 1995 Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550-554
200. Radziuk J, Zhang Z, Wiernsperger N, Pye S 1997 Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes 46:1406-1413
201. Argaud D, Roth H, Wiernsperger N, Leverve XM 1993 Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes. Eur J Biochem 213:1341-1348
202. Large V, Beylot M 1999 Modifications of citric acid cycle activity and gluconeogenesis in streptozotocin-induced diabetes and effects of metformin. Diabetes 48:1251-1257
203. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O, Zhou G, Williamson JM, Ljunqvist O, Efendic S, Moller DE, Thorell A, Goodyear LJ 2002 Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51:2074-2081
204. Fujiwara T, Okuno A, Yoshioka S, Horikoshi H 1995 Suppression of hepatic gluconeogenesis in long-term troglitazone treated diabetic KK and C57BL/KsJ-db/db mice. Metabolism 44:486-490
205. Raman P, Judd RL 2000 Role of glucose and insulin in thiazolidinedione- induced alterations in hepatic gluconeogenesis. Eur J Pharmacol 409:19-29
206. da Tos V, Maran A, Vigili de Kreutzenberg S, Marchetto S, Tadiotto F, Bettio M, Marescotti MC, Tiengo A, Del Prato S 2000 Mechanisms of acute and chronic hypoglycemic action of gliclazide. Acta Diabetol 37:201-206
207. Del Prato S, Vigili de Kreutzenberg S, Riccio A, Tiengo A 1991 Hepatic sensitivity to insulin: effects of sulfonylurea drugs. Am J Med 90:29S-36S
208. Riccio A, Lisato G, de Kreutzenberg SV, Marchetto S, Turrin M, Tiengo A, Del Prato S 1996 Gliclazide potentiates suppression of hepatic glucose production in non-insulin-dependent diabetic patients. Metabolism 45:1196-1202
209. Lechuga CG, Carrillo JJ, Sanchez-Gutierrez JC, Feliu JE 2001 Decreased responsiveness of gluconeogenesis to the modulation by sulfonylureas in hepatocytes isolated from obese (fa/fa) Zucker rats. Life Sci 68:1617-1628
210. Ohlson LO, Larsson B, Bjorntorp P, Eriksson H, Svardsudd K, Welin L, Tibblin G, Wilhelmsen L 1988 Risk factors for type 2 (non-insulin-dependent) diabetes mellitus. Thirteen and one-half years of follow-up of the participants in a study of Swedish men born in 1913. Diabetologia 31:798-805
211. Sandqvist MM, Eriksson JW, Jansson PA 2001 Increased lactate release per fat cell in normoglycemic first-degree relatives of individuals with type 2 diabetes. Diabetes 50:2344-2348
212. Avogaro A, Toffolo G, Miola M, Valerio A, Tiengo A, Cobelli C, Del Prato S 1996 Intracellular lactate- and pyruvate-interconversion rates are increased in muscle tissue of non-insulin-dependent diabetic individuals. J Clin Invest 98:108-115
213. DiGirolamo M, Newby FD, Lovejoy J 1992 Lactate production in adipose tissue: a regulated function with extra-adipose implications. FASEB J 6:2405-2412
214. Vettor R, Lombardi AM, Fabris R, Pagano C, Cusin I, Rohner-Jeanrenaud F, Federspil G, Jeanrenaud B 1997 Lactate infusion in anesthetized rats produces insulin resistance in heart and skeletal muscles. Metabolism 46:684-690
215. Ferrannini E, Natali A, Brandi LS, Bonadonna R, De Kreutzemberg SV, DelPrato S, Santoro D 1993 Metabolic and thermogenic effects of lactate infusion in humans. Am J Physiol 265:E504-E512
216. Paquot N, Schneiter P, Cayeux MC, Chiolero R, Temler E, Jequier E, Tappy L 1995 Effects of infused sodium lactate on glucose and energy metabolism in healthy humans. Diabete Metab 21:345-352
217. Consoli A, Nurjhan N, Reilly Jr JJ, Bier DM, Gerich JE 1990 Mechanism of increased gluconeogenesis in noninsulin-dependent diabetes mellitus. Role of alterations in systemic, hepatic, and muscle lactate and alanine metabolism. J Clin Invest 86:2038-2045
218. Roef MJ, de Meer K, Kalhan SC, Straver H, Berger R, Reijngoud DJ 2003 Gluconeogenesis in humans with induced hyperlactatemia during low-intensity exercise. Am J Physiol Endocrinol Metab 284:E1162-E1171
219. Miller BF, Fattor JA, Jacobs KA, Horning MA, Navazio F, Lindinger MI, Brooks GA 2002 Lactate and glucose interactions during rest and exercise in men: effect of exogenous lactate infusion. J Physiol 544:963-975
220. Stellingwerff T, Watt MJ, Heigenhauser GJ, Spriet LL 2003 Effects of reduced free fatty acid availability on skeletal muscle PDH activation during aerobic exercise. Pyruvate dehydrogenase. Am J Physiol Endocrinol Metab 284:E589-E596
221. DeFronzo RA, Jacot E, Jequier E, Maeder E, Wahren J, Felber JP 1981 The effect of insulin on the disposal of intravenous glucose. Results from indirect calorimetry and hepatic and femoral venous catheterization. Diabetes 30:1000-1007
222. Baron AD, Brechtel G, Wallace P, Edelman SV 1988 Rates and tissue sites of non-insulin- and insulin-mediated glucose uptake in humans. Am J Physiol 255:E769-E774
223. Gloria-Bottini F, Lucarini N, Palmarino R, La Torre M, Nicotra M, Borgiani P, Cosmi E, Bottini E 2001 Phosphoglucomutase genetic polymorphism of newborns. Am J Hum Biol 13:9-14
224. Roach PJ 1990 Control of glycogen synthase by hierarchal protein phosphorylation. FASEB J 4:2961-2968
225. Lawrence Jr JC, Roach PJ 1997 New insights into the role and mechanism of glycogen synthase activation by insulin. Diabetes 46:541-547
226. Alonso MD, Lomako J, Lomako WM, Whelan WJ 1995 A new look at the biogenesis of glycogen. FASEB J 9:1126-1137
227. Manchester J, Skurat AV, Roach P, Hauschka SD, Lawrence Jr JC 1996 Increased glycogen accumulation in transgenic mice overexpressing glycogen synthase in skeletal muscle. Proc Natl Acad Sci USA 93:10707-10711
228. Orho M, Bosshard NU, Buist NR, Gitzelmann R, Aynsley-Green A, Blumel P, Gannon MC, Nuttall FQ, Groop LC 1998 Mutations in the liver glycogen synthase gene in children with hypoglycemia due to glycogen storage disease type 0. J Clin Invest 102:507-515
229. Halse R, Fryer LG, McCormack JG, Carling D, Yeaman SJ 2003 Regulation of glycogen synthase by glucose and glycogen: a possible role for AMP-activated protein kinase. Diabetes 52:9-15
230. Shulman RG, Bloch G, Rothman DL 1995 In vivo regulation of muscle glycogen synthase and the control of glycogen synthesis. Proc Natl Acad Sci USA 92:8535-8542
231. Fernandez-Novell JM, Roca A, Bellido D, Vilaro S, Guinovart JJ 1996 Translocation and aggregation of hepatic glycogen synthase during the fasted-to-refed transition in rats. Eur J Biochem 238:570-575
232. Ferrer JC, Baque S, Guinovart JJ 1997 Muscle glycogen synthase translocates from the cell nucleus to the cystosol in response to glucose. FEBS Lett 415:249-252
233. Dent P, Lavoinne A, Nakielny S, Caudwell FB, Watt P, Cohen P 1990 The molecular mechanism by which insulin stimulates glycogen synthesis in mammalian skeletal muscle. Nature 348:302-308
234. Haystead TA, Sim AT, Carling D, Honnor RC, Tsukitani Y, Cohen P, Hardie DG 1989 Effects of the tumour promoter okadaic acid on intracellular protein phosphorylation and metabolism. Nature 337:78-81
235. Cohen PT 2002 Protein phosphatase 1-targeted in many directions. J Cell Sci 115:241-256
236. Delibegovic M, Armstrong CG, Dobbie L, Watt PW, Smith AJ, Cohen PT 2003 Disruption of the striated muscle glycogen targeting subunit PPP1R3A of protein phosphatase 1 leads to increased weight gain, fat deposition, and development of insulin resistance. Diabetes 52:596-604
237. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA 1995 Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785-789
238. Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, Mills GB 2002 Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway. Mol Cell Biol 22:2099-2110
239. Pap M, Cooper GM 2002 Role of translation initiation factor 2B in control of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3β signaling pathway. Mol Cell Biol 22:578-586
240. Jia J, Amanai K, Wang G, Tang J, Wang B, Jiang J 2002 Shaggy/GSK3 antagonizes Hedgehog signalling by regulating Cubitus interruptus. Nature 416:548-552
241. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR 2000 Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation. Nature 406:86-90
242. Bruno C, DiRocco M, Lamba LD, Bado M, Marino C, Tsujino S, Shanske S, Stella G, Minetti C, van Diggelen OP, DiMauro S 1999 A novel missense mutation in the glycogen branching enzyme gene in a child with myopathy and hepatopathy. Neuromuscul Disord 9:403-407
243. Mu J, Roach PJ 1998 Characterization of human glycogenin-2, a self-glucosylating initiator of liver glycogen metabolism. J Biol Chem 273:34850-34856
244. Lin A, Mu J, Yang J, Roach PJ 1999 Self-glucosylation of glycogenin, the initiator of glycogen biosynthesis, involves an intersubunit reaction. Arch Biochem Biophys 363:163-170
245. Pitcher J, Smythe C, Cohen P 1988 Glycogenin is the priming glucosyltransferase required for the initiation of glycogen biogenesis in rabbit skeletal muscle. Eur J Biochem 176:391-395
246. Baque S, Guinovart JJ, Ferrer JC 1997 Glycogenin, the primer of glycogen synthesis, binds to actin. FEBS Lett 417:355-359
247. Skurat AV, Dietrich AD, Zhai L, Roach PJ 2002 GNIP, a novel protein that binds and activates glycogenin, the self-glucosylating initiator of glycogen biosynthesis. J Biol Chem 277:19331-19338
248. Biorn AC, Graves DJ 2001 The amino-terminal tail of glycogen phosphorylase is a switch for controlling phosphorylase conformation, activation, and response to ligands. Biochemistry 40:5181-5189
249. Hendrickx J, Willems PJ 1996 Genetic deficiencies of the glycogen phosphorylase system. Hum Genet 97:551-556
250. Wolfsdorf JI, Weinstein DA 2003 Glycogen storage diseases. Rev Endocr Metab Disord 4:95-102
251. Burwinkel B, Bakker HD, Herschkovitz E, Moses SW, Shin YS, Kilimann MW 1998 Mutations in the liver glycogen phosphorylase gene (PYGL) underlying glycogenosis type VI. Am J Hum Genet 62:785-791
252. Shaiu WL, Kishnani PS, Shen J, Liu HM, Chen YT 2000 Genotype-phenotype correlation in two frequent mutations and mutation update in type III glycogen storage disease. Mol Genet Metab 69:16-23
253. Pratipanawatr T, Cusi K, Ngo P, Pratipanawatr W, Mandarino LJ, DeFronzo RA 2002 Normalization of plasma glucose concentration by insulin therapy improves insulin-stimulated glycogen synthesis in type 2 diabetes. Diabetes 51:462-468
254. Fery F, Balasse EO 1994 Glucose metabolism during the starved-to-fed transition in obese patients with NIDDM. Diabetes 43:1418-1425
255. Huang X, Vaag A, Hansson M, Weng J, Laurila E, Groop L 2000 Impaired insulin-stimulated expression of the glycogen synthase gene in skeletal muscle of type 2 diabetic patients is acquired rather than inherited. J Clin Endocrinol Metab 85:1584-1590
256. Schalin-Jantti C, Harkonen M, Groop LC 1992 Impaired activation of glycogen synthase in people at increased risk for developing NIDDM. Diabetes 41:598-604
257. Vaag A, Henriksen JE, Beck-Nielsen H 1992 Decreased insulin activation of glycogen synthase in skeletal muscles in young nonobese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus. J Clin Invest 89:782-788
258. Kida Y, Esposito-Del Puente A, Bogardus C, Mott DM 1990 Insulin resistance is associated with reduced fasting and insulin-stimulated glycogen synthase phosphatase activity in human skeletal muscle. J Clin Invest 85:476-481
259. Groop LC, Kankuri M, Schalin-Jantti C, Ekstrand A, Nikula-Ijas P, Widen E, Kuismanen E, Eriksson J, Franssila-Kallunki A, Saloranta C, Koskimies S 1993 Association between polymorphism of the glycogen synthase gene and non-insulin-dependent diabetes mellitus. N Engl J Med 328:10-14
260. Zhang Y, Wat N, Stratton IM, Warren-Perry MG, Orho M, Groop L, Turner RC 1996 UKPDS 19: heterogeneity in NIDDM: separate contributions of IRS-1 and β 3-adrenergic-receptor mutations to insulin resistance and obesity respectively with no evidence for glycogen synthase gene mutations. UK Prospective Diabetes Study. Diabetologia 39:1505-1511
261. Rissanen J, Pihlajamaki J, Heikkinen S, Kekalainen P, Mykkanen L, Kuusisto J, Kolle A, Laakso M 1997 New variants in the glycogen synthase gene (Gln71His, Met416Val) in patients with NIDDM from eastern Finland. Diabetologia 40:1313-1319
262. Cusi K, Consoli A, DeFronzo RA 1996 Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 81:4059-4067
263. Hardie DG 2003 Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 144:5179-5183
264. Mojena M, Marcos ML, Monge L, Feliu JE 1989 Effect of sulfonylureas on hepatic glycogen metabolism: activation of glycogen phosphorylase. Metabolism 38:466-470
265. Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry RR 2000 Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 49:263-271
266. Hansen L, Arden KC, Rasmussen SB, Viars CS, Vestergaard H, Hansen T, Moller AM, Woodgett JR, Pedersen O 1997 Chromosomal mapping and mutational analysis of the coding region of the glycogen synthase kinase-3α and β isoforms in patients with NIDDM. Diabetologia 40:940-946
267. Nikoulina SE, Ciaraldi TP, Mudaliar S, Carter L, Johnson K, Henry RR 2002 Inhibition of glycogen synthase kinase 3 improves insulin action and glucose metabolism in human skeletal muscle. Diabetes 51:2190-2198
268. Morral N 2003 Novel targets and therapeutic strategies for type 2 diabetes. Trends Endocrinol Metab 14:169-175
269. Ring DB, Johnson KW, Henriksen EJ, Nuss JM, Goff D, Kinnick TR, Ma ST, Reeder JW, Samuels I, Slabiak T, Wagman AS, Hammond ME, Harrison SD 2003 Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 52:588-595
270. Hansen L, Hansen T, Vestergaard H, Bjorbaek C, Echwald SM, Clausen JO, Chen YH, Chen MX, Cohen PT, Pedersen O 1995 A widespread amino acid polymorphism at codon 905 of the glycogen-associated regulatory subunit of protein phosphatase-1 is associated with insulin resistance and hypersecretion of insulin. Hum Mol Genet 4:1313-1320
271. Xia J, Scherer SW, Cohen PT, Majer M, Xi T, Norman RA, Knowler WC, Bogardus C, Prochazka M 1998 A common variant in PPP1R3 associated with insulin resistance and type 2 diabetes. Diabetes 47:1519-1524
272. Maegawa H, Shi K, Hidaka H, Iwai N, Nishio Y, Egawa K, Kojima H, Haneda M, Yasuda H, Nakamura Y, Kinoshita M, Kikkawa R, Kashiwagi A 1999 The 3′-untranslated region polymorphism of the gene for skeletal muscle-specific glycogen-targeting subunit of protein phosphatase 1 in the type 2 diabetic Japanese population. Diabetes 48:1469-1472
273. Savage DB, Agostini M, Barroso I, Gurnell M, Luan J, Meirhaeghe A, Harding AH, Ihrke G, Rajanayagam O, Soos MA, George S, Berger D, Thomas EL, Bell JD, Meeran K, Ross RJ, Vidal-Puig A, Wareham NJ, O'Rahilly S, Chatterjee VK, Schafer AJ 2002 Digenic inheritance of severe insulin resistance in a human pedigree. Nat Genet 31:379-384
274. Hegele RA, Harris SB, Zinman B, Wang J, Cao H, Hanley AJ, Tsui LC, Scherer SW 1998 Variation in the AU(AT)-rich element within the 3′-untranslated region of PPP1R3 is associated with variation in plasma glucose in aboriginal Canadians. J Clin Endocrinol Metab 83:3980-3983
275. Shen GQ, Ikegami H, Kawaguchi Y, Fujisawa T, Hamada Y, Ueda H, Shintani M, Nojima K, Kawabata Y, Yamada K, Babaya N, Ogihara T 1998 Asp905Tyr polymorphism of the gene for the skeletal muscle-specific glycogen-targeting subunit of protein phosphatase 1 in NIDDM. Diabetes Care 21:1086-1089
276. Hansen L, Reneland R, Berglund L, Rasmussen SK, Hansen T, Lithell H, Pedersen O 2000 Polymorphism in the glycogen-associated regulatory subunit of type 1 protein phosphatase (PPP1R3) gene and insulin sensitivity. Diabetes 49:298-301
277. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA 2000 Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053-4059
278. Christiansen MP, Linfoot PA, Neese RA, Hellerstein MK 2000 Effect of dietary energy restriction on glucose production and substrate utilization in type 2 diabetes. Diabetes 49:1691-1699
279. Martin WH, Hoover DJ, Armento SJ, Stock IA, McPherson RK, Danley DE, Stevenson RW, Barrett EJ, Treadway JL 1998 Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo. Proc Natl Acad Sci USA 95:1776-1781
280. Aiston S, Hampson L, Gomez-Foix AM, Guinovart JJ, Agius L 2001 Hepatic glycogen synthesis is highly sensitive to phosphorylase activity: evidence from metabolic control analysis. J Biol Chem 276:23858-23866
281. West IC 2000 Radicals and oxidative stress in diabetes. Diabet Med 17:171-180
282. Vulliamy TJ, D'Urso M, Battistuzzi G, Estrada M, Foulkes NS, Martini G, Calabro V, Poggi V, Giordano R, Town M, Luzzatto L, Persico MG 1988 Diverse point mutations in the human glucose-6-phosphate dehydrogenase gene cause enzyme deficiency and mild or severe hemolytic anemia. Proc Natl Acad Sci USA 85:5171-5175
283. Kugler W, Breme K, Laspe P, Muirhead H, Davies C, Winkler H, Schroter W, Lakomek M 1998 Molecular basis of neurological dysfunction coupled with haemolytic anaemia in human glucose-6-phosphate isomerase (GPI) deficiency. Hum Genet 103:450-454
284. Marshall S, Bacote V, Traxinger RR 1991 Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem 266:4706-4712
285. Milewski S 2002 Glucosamine-6-phosphate synthase-the multi-facets enzyme. Biochim Biophys Acta 1597:173-192
286. Wells L, Vosseller K, Hart GW 2001 Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 291:2376-2378
287. McClain DA, Crook ED 1996 Hexosamines and insulin resistance. Diabetes 45:1003-1009
288. Traxinger RR, Marshall S 1991 Coordinated regulation of glutamine:fructose-6-phosphate amidotransferase activity by insulin, glucose, and glutamine. Role of hexosamine biosynthesis in enzyme regulation. J Biol Chem 266:10148-10154
289. Wang J, Liu R, Hawkins M, Barzilai N, Rossetti L 1998 A nutrient-sensing pathway regulates leptin gene expression in muscle and fat. Nature 393:684-688
290. Obici S, Wang J, Chowdury R, Feng Z, Siddhanta U, Morgan K, Rossetti L 2002 Identification of a biochemical link between energy intake and energy expenditure. J Clin Invest 109:1599-1605
291. Baron AD, Zhu JS, Zhu JH, Weldon H, Maianu L, Garvey WT 1995 Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implications for glucose toxicity. J Clin Invest 96:2792-2801
292. Hawkins M, Hu M, Yu J, Eder H, Vuguin P, She L, Barzilai N, Leiser M, Backer JM, Rossetti L 1999 Discordant effects of glucosamine on insulin-stimulated glucose metabolism and phosphatidylinositol 3-kinase activity. J Biol Chem 274:31312-31319
293. Robinson KA, Sens DA, Buse MG 1993 Pre-exposure to glucosamine induces insulin resistance of glucose transport and glycogen synthesis in isolated rat skeletal muscles. Study of mechanisms in muscle and in rat-1 fibroblasts overexpressing the human insulin receptor. Diabetes 42:1333-1346
294. Crook ED, Zhou J, Daniels M, Neidigh JL, McClain DA 1995 Regulation of glycogen synthase by glucose, glucosamine, and glutamine:fructose-6-phosphate amidotransferase. Diabetes 44:314-320
295. Crook ED, Crenshaw G, Veerababu G, Singh LP 2000 Overexpression of glutamine:fructose-6-phosphate amidotransferase in rat-1 fibroblasts enhances glucose-mediated glycogen accumulation via suppression of glycogen phosphorylase activity. Endocrinology 141:1962-1970
296. Barzilai N, Hawkins M, Angelov I, Hu M, Rossetti L 1996 Glucosamine-induced inhibition of liver glucokinase impairs the ability of hyperglycemia to suppress endogenous glucose production. Diabetes 45:1329-1335
297. Balkan B, Dunning BE 1994 Glucosamine inhibits glucokinase in vitro and produces a glucose-specific impairment of in vivo insulin secretion in rats. Diabetes 43:1173-1179
298. Traxinger RR, Marshall S 1992 Insulin regulation of pyruvate kinase activity in isolated adipocytes. Crucial role of glucose and the hexosamine biosynthesis pathway in the expression of insulin action. J Biol Chem 267:9718-9723
299. Hawkins M, Barzilai N, Liu R, Hu M, Chen W, Rossetti L 1997 Role of the glucosamine pathway in fat-induced insulin resistance. J Clin Invest 99:2173-2182
300. Hebert Jr LF, Daniels MC, Zhou J, Crook ED, Turner RL, Simmons ST, Neidigh JL, Zhu JS, Baron AD, McClain DA 1996 Overexpression of glutamine:fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance. J Clin Invest 98:930-936
301. Tang J, Neidigh JL, Cooksey RC, McClain DA 2000 Transgenic mice with increased hexosamine flux specifically targeted to β-cells exhibit hyperinsulinemia and peripheral insulin resistance. Diabetes 49:1492-1499
302. Yki-Jarvinen H, Daniels MC, Virkamaki A, Makimattila S, De-Fronzo RA, McClain D 1996 Increased glutamine:fructose-6-phosphate amidotransferase activity in skeletal muscle of patients with NIDDM. Diabetes 45:302-307
303. Daniels MC, Ciaraldi TP, Nikoulina S, Henry RR, McClain DA 1996 Glutamine:fructose-6-phosphate amidotransferase activity in cultured human skeletal muscle cells: relationship to glucose disposal rate in control and non-insulin-dependent diabetes mellitus subjects and regulation by glucose and insulin. J Clin Invest 97:1235-1241
304. Considine RV, Cooksey RC, Williams LB, Fawcett RL, Zhang P, Ambrosius WT, Whitfield RM, Jones R, Inman M, Huse J, McClain DA 2000 Hexosamines regulate leptin production in human subcutaneous adipocytes. J Clin Endocrinol Metab 85:3551-3556
305. Monauni T, Zenti MG, Cretti A, Daniels MC, Targher G, Caruso B, Caputo M, McClain D, Del Prato S, Giaccari A, Muggeo M, Bonora E, Bonadonna RC 2000 Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes 49:926-935
306. Brownlee M 2001 Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820
307. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M 2001 Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 108:1341-1348
308. Goldberg HJ, Scholey J, Fantus IG 2000 Glucosamine activates the plasminogen activator inhibitor 1 gene promoter through Sp1 DNA binding sites in glomerular mesangial cells. Diabetes 49:863-871
309. Singh LP, Andy J, Anyamale V, Greene K, Alexander M, Crook ED 2001 Hexosamine-induced fibronectin protein synthesis in mesangial cells is
310. Federici M, Menghini R, Mauriello A, Hribal ML, Ferrelli F, Lauro D, Sbraccia P, Spagnoli LG, Sesti G, Lauro R 2002 Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation 106:466-472
311. Du XL, Edelstein D, Rossetti L, Fantus IG, Goldberg H, Ziyadeh F, Wu J, Brownlee M 2000 Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 97:12222-12226
312. Nerlich AG, Sauer U, Kolm-Litty V, Wagner E, Koch M, Schleicher ED 1998 Expression of glutamine:fructose-6-phosphate amidotransferase in human tissues: evidence for high variability and distinct regulation in diabetes. Diabetes 47:170-178